IIT Alumni Council announces setting up of Engineered Biomolecule Mega Incubator for startups against Covid19

Spread over 2.5 million square feet area the Engineered Biomolecule Mega Incubator (EBMI) initiative to align startups in India’s offensive against Covid19  will be  the largest incubator of its kind in the world.  EBMI will have direct access to over 30,000 PhDs through TieNet and a virtual presence in every smartphone. The captive 100,000 sqft pilot plant facility for biomolecule manufacturing to be set up in the NCR Area.

According to a statement from IIT Alumni Council , the MegaIncubator is architected smartly, stitching together existing cutting edge infrastructure to create an end-to-end phygital support system for aspiring Biomolecule startups, thereby accelerating the time to market manifold. “The MegaIncubator will be global and aspires to reach out to any technocrat startup promoter anywhere in the world that is pursuing deep technology in the Biomolecule domain. Using a mobile app, it would be possible to onboard an incubatee virtually at the speed of thought,” the statement claimed.

“Given that over 70% of a RTPCR or NGS test kit in value terms are biomolecules, we understand the need and urgency of focusing on this domain. Most advanced biotherapeutic drugs from insulin to interferon to plasma antibodies are biomolecules. We believe that we can influence a very substantial cost and price reduction in bio-therapeutics. The ultimate goal of IIT Alumni Council is to make sure that every person in India is able to afford genetic tests like Covid19 and biotherapeutic treatment,” said Ravi Sharma, President, IIT Alumni Council.

Engineered biomolecules play a key role in molecular diagnostics, genetic testing as well as biotherapeutics, besides a host of applications in sectors varying from water treatment and agriculture to advanced genetics.

 “A dedicated global team has been working 24/7 on the EBMI since March end. We would like to thank Hyde Consulting, Grant Thornton and the tens of volunteers who have helped to take EBMI from thought to Project in less than 100 days. We have also received over twenty incubatee proposals to deliver products such as viral lysis solution, viral transport medium, Lyophilized room temperature stable, RTPCR kits, plasma derived immunoglobins (IVIG), antibody libraries to develop and manufacture recombinant therapeutic antibodies etc. We are also looking at genetic cloning of nature derived peptides and have studied major global training centers for biologics development and manufacturing,” added Dr Samir Kulkarni, Director of Innovation and National Centre for Nanoscience and Nanotechnology, University of Mumbai which is an institutional partner of EBM